🇺🇸 FDA
Pipeline program

BI 201335

1220.48

Phase 3 small_molecule completed

Quick answer

BI 201335 for Hepatitis C is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim
Indication
Hepatitis C
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials